The transcriptional coactivator p300/CBP (CREBBP) is a histone acetyltransferase (HAT) that regulates gene expression by acetylating histones and other transcription factors. Dysregulation of p300/CBP HAT activity contributes to various diseases including cancer. Sequence alignments, enzymology experiments and inhibitor studies on p300/CBP have led to contradictory results about its catalytic mechanism and its structural relation to the Gcn5/PCAF and MYST HATs. Here we describe a high-resolution X-ray crystal structure of a semi-synthetic heterodimeric p300 HAT domain in complex with a bi-substrate inhibitor, Lys-CoA. This structure shows that p300/CBP is a distant cousin of other structurally characterized HATs, but reveals several novel features that explain the broad substrate specificity and preference for nearby basic residues. Based on this structure and accompanying biochemical data, we propose that p300/CBP uses an unusual 'hit-and-run' (Theorell-Chance) catalytic mechanism that is distinct from other characterized HATs. Several disease-associated mutations can also be readily accounted for by the p300 HAT structure. These studies pave the way for new epigenetic therapies involving modulation of p300/CBP HAT activity.
Ghrelin is a gastric peptide hormone that stimulates weight gain in vertebrates. The biological activities of ghrelin require octanoylation of the peptide on Ser3, an unusual post-translational modification that is catalyzed by the enzyme ghrelin O-acyltransferase (GOAT). Here, we describe the design, synthesis, and characterization of GO-CoA-Tat, a peptide-based bisubstrate analog that antagonizes GOAT. GO-CoA-Tat potently inhibits GOAT in vitro, in cultured cells, and in mice. Intraperitoneal administration of GO-CoA-Tat improves glucose tolerance and reduces weight gain in wild-type mice but not in ghrelin-deficient mice, supporting the concept that its beneficial metabolic effects are due specifically to GOAT inhibition. In addition to serving as a research tool for mapping ghrelin actions, GO-CoA-Tat may help pave the way for clinical targeting of GOAT in metabolic diseases.The persistent rise in the proportion of overweight individuals in Western society over the past 30 years has been associated with substantial excess morbidity and is widely recognized as a major public health concern. To address this problem, intensive efforts are underway to ‡ To whom correspondence should be addressed. pcole@jhmi.edu. * These authors contributed equally to this work. † These authors contributed equally to this work. clarify nutrient-hormone interactions contributing to weight gain. Starting with the isolation of leptin (1), a series of hormones acting centrally and peripherally to influence body mass have been discovered. Among these, the gastric peptide hormone acyl ghrelin has generated considerable interest as an important stimulus for weight gain (2-5) and modulator of glucose homeostasis (6-8). Various strategies in therapeutic development have been devised to antagonize acyl ghrelin (9,10), although none has yet emerged as clinically beneficial. Acyl ghrelin has an unusual Ser3 octanoylation; only acylated ghrelin can bind and activate the growth hormone secretagogue receptor (GHSR-1a). The cDNA for the enzyme responsible for this esterification, GOAT, has recently been cloned (11,12). GOAT has been suggested as a potential therapeutic target for modulating weight gain and glucose control, but thishas not yet been directly tested (9,13). An acyl ghrelin product analog Dap-ghrelin blocks GOAT activity in a microsomal assay (14).We designed bisubstrate analog GO-CoA-Tat based on the theory that if GOAT uses a ternary complex mechanism which templates octanoyl-CoA and ghrelin peptide, then linking the two substrates with a non-cleavable bridge could combine the binding energies of the individual ligands without the entropic loss associated with forming the ternary complex (Fig. 1A). A related strategy has been used for other peptide modifying enzymes including histone acetyltransferases (HAT) and protein kinases (15,16). Since we were uncertain about the ghrelin peptide length needed for recognition by GOAT, we selected amino acids 1-10 for coupling to octanoyl-CoA, to maximize inclusion of highly conserved...
Sulforaphane [1-isothiocyanato-4-(methylsulfinyl)butane], a naturally occurring isothiocyanate derived from cruciferous vegetables, is a highly potent inducer of phase 2 cytoprotective enzymes and can protect against electrophiles including carcinogens, oxidative stress, and inflammation. The mechanism of action of sulforaphane is believed to involve modifications of critical cysteine residues of Keap1, which lead to stabilization of Nrf2 to activate the antioxidant response element of phase 2 enzymes. However, the dithiocarbamate functional group formed by a reversible reaction between isothiocyanate of sulforaphane and sulfhydryl nucleophiles of Keap1 is kinetically labile, and such modification in intact cells has not yet been demonstrated. Here we designed sulforaphane analogs with replacement of the reactive isothiocyanate by the more gentle electrophilic sulfoxythiocarbamate group that also selectively targets cysteine residues in proteins but forms stable thiocarbamate adducts. Twenty-four sulfoxythiocarbamate analogs were synthesized that retain the structural features important for high potency in sulforaphane analogs: the sulfoxide or keto group and its appropriate distance to electrophilic functional group. Evaluation in various cell lines including hepatoma cells, retinal pigment epithelial cells, and keratinocytes as well as in mouse skin shows that these analogs maintain high potency and efficacy for phase 2 enzyme induction as well as the inhibitory effect on lipopolysaccharide-induced nitric oxide formation like sulforaphane. We further show in living cells that a sulfoxythiocarbamate analog can label Keap1 on several key cysteine residues as well as other cellular proteins offering new insights into the mechanism of chemoprotection.
Background:Ghrelin O-acyltransferase (GOAT) is a membrane protein that is responsible for octanoylating the metabolism-regulating peptide hormone ghrelin. Results: We have used a combination of approaches to determine the topology of GOAT. Conclusion:We have shown that GOAT has 11 transmembrane-spanning domains and one reentrant loop. Significance: These findings serve as a reference for other membrane-bound O-acyltransferase family members.
Protein acetylation on Lys residues is recognized as a significant post-translational modification in cells, but it is often difficult to discern the direct structural and functional effects of individual acetylation events. Here we describe a new tool, methylthiocarbonyl-aziridine, to install acetylLys mimics site-specifically into peptides and proteins by alkylation of Cys residues. We demonstrate that the resultant thiocarbamate modification can be recognized by the Brdt bromodomain and site-specific anti-acetyl-Lys antibodies, is resistant to histone deacetylase cleavage, and can confer activation of the histone acetyltransferase Rtt109 by simulating autoacetylation. We also use this approach to obtain functional evidence that acetylation of CK2 protein kinase on Lys102 can stimulate its catalytic activity.Reversible acetylation of histones catalyzed by histone acetyltransferases (HATs) and histone deacetylases (HDACs) is recognized as a central mechanism of chromatin regulation. Beyond histones, Lys acetylation has been observed in more than 2500 mammalian proteins on more than 4000 sites and has been shown to govern many biological processes.1 Several approaches are available to explore the structural and functional consequences of protein acetylation. Traditional site-directed mutagenesis is used to replace Lys with Arg or Gln to provide indirect insights into Lys acetylation. Expressed protein ligation and unnatural amino acid mutagenesis via nonsense suppression can install acetylLys (AcK) at desired protein sites but have various technical limitations.2 pcole@jhmi.edu. Supporting Information Available. Detailed experimental procedures and Figures S1-S10. This material is available free of charge via the Internet at http://pubs.acs.org. NIH Public AccessAuthor Manuscript J Am Chem Soc. Author manuscript; available in PMC 2011 July 28. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptAs an analog of methyl-Lys, methyl-thiaLys can be introduced at targeted protein locations via a relatively simple strategy involving Cys alkylation with N-methyl-aminoethylbromide derivatives.3 To create an acetyl-thiaLys analog (Figure 1a), we attempted to use the corresponding acetamide reagent with Cys-containing peptide; however, no significant conversion was observed. We hypothesized that the reduced ability of the amide compounds to form three-membered ring intermediates and/or intramolecular imidate formation led to diminished activity of N-acetyl-aminoethylbromide. We then explored the reaction of Nacetyl-aziridine and a Cys-containing peptide (Figure 1b). The predominant product observed by mass spectrometry was M+42 suggesting that acetyl-aziridine treatment led to an undesired acetyl transfer by nucleophilic attack at the carbonyl rather than the aziridine methylene ( Figure S1).To reduce reactivity at the carbonyl, we explored methylthiocarbonyl-aziridine (MTCA) (Figure 1b).4 Cys alkylation with this reagent was proposed to provide methylthiocarbonylthiaLys (MTCTK), a thiocarbama...
Expressed protein ligation is a valuable method for protein semisynthesis that involves the reaction of recombinant protein C-terminal thioesters with N-Cys containing peptides but the requirement of a Cys residue at the ligation junction can limit its use. Here we employ subtiligase variants to efficiently ligate Cys-free peptides to protein thioesters. Using this method, we have more accurately determined the effect of C-terminal phosphorylation on the tumor suppressor protein PTEN.
Ghrelin-O-Acyltransferase (GOAT) is an 11-transmembrane integral membrane protein that octanoylates the metabolism-regulating peptide hormone ghrelin at Ser3 and may represent an attractive target for the treatment of type II diabetes and the metabolic syndrome. Protein octanoylation is unique to ghrelin in humans, and little is known about the mechanism of GOAT or of related protein-O-acyltransferases HHAT or PORC. In this study, we explored an in vitro microsomal ghrelin octanoylation assay to analyze its enzymologic features. Measurement of Km for 10-mer, 27-mer, and synthetic Tat-peptide-containing ghrelin substrates provided evidence for a role of charge interactions in substrate binding. Ghrelin substrates with amino-alanine in place of Ser3 demonstrated that GOAT can catalyze the formation of an octanoyl-amide bond at a similar rate compared with the natural reaction. A pH-rate comparison of these substrates revealed minimal differences in acyltransferase activity across pH 6.0–9.0, providing evidence that these reactions may be relatively insensitive to the basicity of the substrate nucleophile. The conserved His338 residue was required both for Ser3 and amino-Ala3 ghrelin substrates, suggesting that His338 may have a key catalytic role beyond that of a general base.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.